COVID-19 vaccines: breaking record times to first-in-human trials

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

A novel coronavirus outbreak of global health concern

Wang, C., Horby, P. W., Hayden, F. G., & Gao, G. F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30185-9 · Cited by 7,700

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677

Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

Rothe, C., Schunk, M., Sothmann, P., Bretzel, G., Froeschl, G., Wallrauch, C., Zimmer, T., Thiel, V., Jänke, C., Guggemos, W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001468 · Cited by 4,211

Zika Virus Outbreak on Yap Island, Federated States of Micronesia

Duffy, M. R., Chen, T.-H., Hancock, W. T., Powers, A. M., Kool, J. L., Lanciotti, R. S., Pretrick, M., Marfel, M., Holzbauer, S., Dubray, C. L., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805715 · Cited by 3,130

Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak

Wilder-Smith, A., & Freedman, D. O. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa020 · Cited by 2,727

Zika Virus (I). Isolations and serological specificity

Dick, G. W. A., Kitchen, S. F., & Haddow, A. J. (1952) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(52)90042-4 · Cited by 2,698

Research on Dengue during World War II

Sabin, A. B. (1952) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1952.1.30 · Cited by 955

Zika virus (II). Pathogenicity and physical properties

Dick, G. W. A. (1952) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(52)90043-6 · Cited by 690

The Newala epidemic: III. The virus: isolation, pathogenic properties and relationship to the epidemic

Ross, R. W. (1956) · Journal of Hygiene · doi:10.1017/s0022172400044442 · Cited by 650

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555

Behavioural nudges increase COVID-19 vaccinations

Dai, H., Saccardo, S., Han, M. A., Roh, L., Raja, N., Vangala, S., Modi, H., Pandya, S., Sloyan, M., & Croymans, D. M. (2021) · Nature · doi:10.1038/s41586-021-03843-2 · Cited by 462

COVID-19 Vaccine Frontrunners and Their Nanotechnology Design

Chung, Y. H., Beiss, V., Fiering, S., & Steinmetz, N. F. (2020) · ACS Nano · doi:10.1021/acsnano.0c07197 · Cited by 354

AI bias: exploring discriminatory algorithmic decision-making models and the application of possible machine-centric solutions adapted from the pharmaceutical industry

Belenguer, L. (2022) · AI and Ethics · doi:10.1007/s43681-022-00138-8 · Cited by 289

An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study

Yang, Z., Bogdan, P., & Nazarian, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-81749-9 · Cited by 271

Vaccines for COVID-19

Tregoning, J. S., Brown, E. S., Cheeseman, H. M., Flight, K. E., Higham, S. L., Lemm, N.-M., Pierce, B. F., Stirling, D. C., Wang, Z., & Pollock, K. M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13517 · Cited by 226

T‐cell responses and therapies against SARS‐CoV‐2 infection

Toor, S. M., Saleh, R., Nair, V. S., Taha, R. Z., & Elkord, E. (2020) · Immunology · doi:10.1111/imm.13262 · Cited by 208

A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic

Funk, C. D., Laferrière, C. A., & Ardakani, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00937 · Cited by 204

Emerging Technologies for Use in the Study, Diagnosis, and Treatment of Patients with COVID-19

Tsikala Vafea, M., Atalla, E., Georgakas, J., Shehadeh, F., Mylona, E. K., Kalligeros, M., & Mylonakis, E. (2020) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-020-00629-w · Cited by 153

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

Rabaan, A. A., Al-Ahmed, S. H., Sah, R., Tiwari, R., Yatoo, M. I., Patel, S. K., Pathak, M., Malik, Y. S., Dhama, K., Singh, K. P., et al. (2020) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-020-00384-w · Cited by 157

The recent challenges of highly contagious COVID‐19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy

Mohapatra, R. K., Pintilie, L., Kandi, V., Sarangi, A. K., Das, D., Sahu, R., & Perekhoda, L. O. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13761 · Cited by 132

An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times

Montero, C. G., Fraile‐Μartinez, O., Bravo, C., Torres‐Carranza, D., Sánchez‐Trujillo, L., Gomez-Lahoz, A. M., Guijarro, L. G., García‐Honduvilla, N., Asúnsolo, Á., Buján, J., et al. (2021) · Vaccines · doi:10.3390/vaccines9050433 · Cited by 112

Smartphone apps in the COVID-19 pandemic

Pandit, J. A., Radin, J. M., Quer, G., & Topol, E. J. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01350-x · Cited by 101

Geriatric Population During the COVID-19 Pandemic: Problems, Considerations, Exigencies, and Beyond

Dhama, K., Patel, S. K., Kumar, R., Rana, J., Yatoo, M. I., Kumar, A., Tiwari, R., Dhama, J., Natesan, S., Singh, R. P., et al. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.574198 · Cited by 98

The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines

Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Pires, V. C., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Moret, M. A., & Badaró, R. J. D. S. (2022) · Vaccines · doi:10.3390/vaccines10040591 · Cited by 79

The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development

Alturki, S. O., Alturki, S. O., Connors, J. R., Cusimano, G. M., Kutzler, M. A., Izmirly, A. M., & Haddad, E. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01880 · Cited by 80

Next-Generation Sequencing for Confronting Virus Pandemics

Quer, J., Colomer‐Castell, S., de Campos, C. F., Andrés, C., Piñana, M., Cortese, M. F., Gónzalez‐Sánchez, A., García‐Cehic, D., Ibañez‐Lligoña, M., Pumarola, T., et al. (2022) · Viruses · doi:10.3390/v14030600 · Cited by 78

An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic

Jamwal, S., Gautam, A., Elsworth, J. D., Kumar, M., Chawla, R., & Kumar, P. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118105 · Cited by 71

Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects

Zhang, Z., Shen, Q., & Chang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.843928 · Cited by 69

Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review)

Vivarelli, S., Falzone, L., Torino, F., Scandurra, G., Russo, G. L., Bordonaro, R., Pappalardo, F., Spandidos, D. A., Raciti, G., & Libra, M. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5159 · Cited by 64

Recent advances in immunotherapies against infectious diseases

Ramamurthy, D., Nundalall, T., Cingo, S., Mungra, N., Karaan, M., Naran, K., & Barth, S. (2020) · Immunotherapy Advances · doi:10.1093/immadv/ltaa007 · Cited by 63

Predicting COVID-19 Vaccination Intention: The Determinants of Vaccine Hesitancy

Fernandes, N., Costa, D., Costa, D., Keating, J., & Arantes, J. (2021) · Vaccines · doi:10.3390/vaccines9101161 · Cited by 60

Assessment of Knowledge, Perception and Readiness of Nigerians to Participate in the COVID-19 Vaccine Trial

Enitan, S. S., Oyekale, A. O., Akele, R. Y., Olawuyi, K. A., Olabisi, E. O., Nwankiti, A. J., Adejumo, E., & Enitan, C. B. (2020) · International Journal of Vaccines and Immunization · doi:10.16966/2470-9948.123 · Cited by 61

Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives

Vivekanandhan, K., Poornima, S., Barabadi, H., Arumugam, V., Raj, D. D. R. D. P., Manikandan, S., Subbaiya, R., Anand, K., Pandi, B., Chandrasekaran, B., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.604447 · Cited by 60

Analysis of the COVID-19 Vaccine Development Process: an Exploratory Study of Accelerating Factors and Innovative Environments

Defendi, H. G. T., Madeira, L. D. S., & Borschiver, S. (2021) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-021-09535-8 · Cited by 63

Pandemics are catalysts of scientific novelty: Evidence from COVID ‐19

Liu, M., Bu, Y., Chen, C., Xu, J., Li, D., Leng, Y., Freeman, R. B., Meyer, E. T., Yoon, W., Sung, M., et al. (2021) · Journal of the Association for Information Science and Technology · doi:10.1002/asi.24612 · Cited by 62

Subunit vaccines for Acinetobacter baumannii

Yang, N., Jin, X., Zhu, C., Gao, F., Weng, Z., Du, X., & Feng, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1088130 · Cited by 53

Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India

Behera, P., Singh, A. K., Subba, S. H., Arjun, M. C., Sahu, D. P., Chandanshive, P. D., Pradhan, S. K., Parida, S. P., Mishra, A., Patro, B. K., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2034456 · Cited by 51

Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines

Dhawan, M. K., Rabaan, A. A., Fawarah, M. M., Almuthree, S. A., Alsubki, R. A., Alfaraj, A. H., Mashraqi, M. M., Alshamrani, S., Abduljabbar, W. A., Alwashmi, A. S. S., et al. (2023) · Vaccines · doi:10.3390/vaccines11010101 · Cited by 45

Rethinking Clinical Trials Reform During the COVID-19 Pandemic

Nabhan, C., Choueiri, T. K., & Mato, A. R. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3142 · Cited by 41

The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants

Inchingolo, A. D., Dipalma, G., Inchingolo, A. M., Malcangi, G., Santacroce, L., D’Oria, M. T., Isacco, C. G., Bordea, I. R., Candrea, S., Scarano, A., et al. (2021) · Antioxidants · doi:10.3390/antiox10060881 · Cited by 54

Promising Acinetobacter baumannii Vaccine Candidates and Drug Targets in Recent Years

Tan, Y. C., & Lahiri, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.900509 · Cited by 41

The Prevalence of Multidrug-Resistant Acinetobacter baumannii and Its Vaccination Status among Healthcare Providers

Elbehiry, A., Marzouk, E., Moussa, I. M., Mushayt, Y., Algarni, A. A., Alrashed, O., Alghamdi, K., Almutairi, N. M., Anagreyyah, S. A., Alzahrani, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11071171 · Cited by 39

COVID‐19: Emergence of Infectious Diseases, Nanotechnology Aspects, Challenges, and Future Perspectives

Gupta, A., Kumar, S., Kumar, R., Choudhary, A. K., Kumari, K., Singh, P., & Kumar, V. (2020) · ChemistrySelect · doi:10.1002/slct.202001709 · Cited by 35

Chikungunya Virus: Priority Pathogen or Passing Trend?

Zurbia-Flores, G. M., Reyes‐Sandoval, A., & Kim, Y. C. (2023) · Vaccines · doi:10.3390/vaccines11030568 · Cited by 33

Human SARS-CoV-2 has evolved to increase U content and reduce genome size

Wang, Y. L., Chen, X., Yang, L., Yao, Q., & Chen, K. P. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.02.034 · Cited by 31

An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)

Bahrami, A. A., Azargoonjahromi, A., Sadraei, S., Aarabi, A., Payandeh, Z., & Rajabibazl, M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00339-3 · Cited by 33

Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines

Zurbia-Flores, G. M., Rollier, C. S., & Reyes‐Sandoval, A. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1895644 · Cited by 28

Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments

Akter, R., Rahman, M. H., Bhattacharya, T., Kaushik, D. K., Mittal, V., Parashar, J., Kumar, K., Kabir, M. T., & Tagde, P. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16809-8 · Cited by 28

Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines

Malburet, C., Leclercq, L., Cotte, J., Thiebaud, J., Bazin, E., Garinot, M., & Cottet, H. (2022) · Gene Therapy · doi:10.1038/s41434-022-00370-1 · Cited by 29

Addressing the illegal wildlife trade in the European Union as a public health issue to draw decision makers attention

Halbwax, M. (2020) · Biological Conservation · doi:10.1016/j.biocon.2020.108798 · Cited by 25

Data-Driven and Technology-Enabled Trial Innovations Toward Decentralization of Clinical Trials: Opportunities and Considerations

Sehrawat, O., Noseworthy, P. A., Siontis, K. C., Haddad, T. C., Halamka, J. D., & Liu, H. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.02.003 · Cited by 29

COVID-19 in Kidney Transplantation: Epidemiology, Management Considerations, and the Impact on Kidney Transplant Practice

Kataria, A., Yakubu, I., Winstead, R. J., Gowda, M., & Gupta, G. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000001031 · Cited by 25

Immunotherapeutics for Covid-19 and post vaccination surveillance

Kumar, N. S. S., Chintagunta, A. D., Kumar, S., Roy, S., & Kumar, M. (2020) · 3 Biotech · doi:10.1007/s13205-020-02522-9 · Cited by 25

Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic

Chakraborty, C., Sharma, A. R., Bhattacharya, M., Sharma, G., Saha, R. P., & Lee, S. (2021) · Immune Network · doi:10.4110/in.2021.21.e5 · Cited by 26

Direct Comparison of N-Glycans and Their Isomers Derived from Spike Glycoprotein 1 of MERS-CoV, SARS-CoV-1, and SARS-CoV-2

Cho, B. G., Gautam, S., Peng, W., Huang, Y., Goli, M., & Mechref, Y. S. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00323 · Cited by 25

The COVID-19 pandemic as a long-term school crisis: Impact, risk, resilience, and crisis management.

Nickerson, A. B., & Sulkowski, M. L. (2021) · School Psychology · doi:10.1037/spq0000470 · Cited by 34

FASN inhibitor TVB-3166 prevents S-acylation of the spike protein of human coronaviruses

Mekhail, K., Lee, M., Sugiyama, M. G., Astori, A., St‐Germain, J. R., Latreille, E., Khosraviani, N., Wei, K., Li, Z., Rini, J. M., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100256 · Cited by 26

Strategy, coordinated implementation, and sustainable financing needed for COVID-19 innovations

Dzau, V. J., & Balatbat, C. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32289-3 · Cited by 25

Microorganisms as Shapers of Human Civilization, from Pandemics to Even Our Genomes: Villains or Friends? A Historical Approach

Rodríguez‐Frias, F., Quer, J., Tabernero, D., Cortese, M. F., García-García, S., Rando‐Segura, A., & Pumarola, T. (2021) · Microorganisms · doi:10.3390/microorganisms9122518 · Cited by 26

The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts

Khan, I., Ahmed, Z., Sarwar, A., Jamil, A. R., & Anwer, F. (2020) · Cureus · doi:10.7759/cureus.8871 · Cited by 22

Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines

Neto, A. R. D. S., de Carvalho, A. R. B., da Silva, M. D. F., Neta, M. M. R., Sena, I. V. D. O., Almeida, R. N., Filha, F. S. S. C., Silva, L. L. L. E., da Costa, G. R., Lira, I. M. D. S., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064796 · Cited by 20

Projecting the impact of Covid-19 variants and vaccination strategies in disease transmission using a multilayer network model in Costa Rica

García, Y. E., Mery, G., Vásquez, P., Calvo, J. G., Barboza, L. A., Rivas, T., & Sánchez, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-06236-1 · Cited by 17

Application of Optimal Control of Infectious Diseases in a Model-Free Scenario

Nepomuceno, E. G., Peixoto, M. L. C., Lacerda, M. J., Campanharo, A. S. L. O., Takahashi, R. H. C., & Aguirre, L. A. (2021) · SN Computer Science · doi:10.1007/s42979-021-00794-3 · Cited by 16

Global scenario, public health concerns and mitigation strategies to counter current ongoing SARS-CoV-2 / COVID-19 pandemic

Barbuddhe, S. B., Rawool, D. B., Gaonkar, P. P., Vergis, J., Dhama, K., & Malik, S. V. S. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1810496 · Cited by 15

A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials

Jeyanthi, V., Govindarajan, V. K., Sekaran, S., & Venkatapathy, S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.637378 · Cited by 15

COVID-19 vaccinations: An overview of the Italian national health system's online communication from a citizen perspective

Pirrotta, L., Guidotti, E., Tramontani, C., Bignardelli, E., Venturi⋄, G., & Rosis, S. D. (2022) · Health Policy · doi:10.1016/j.healthpol.2022.08.001 · Cited by 15

Multi-Antigenic Virus-like Particle of SARS CoV-2 produced in Saccharomyces cerevisiae as a vaccine candidatePreprint

Arora, K., Rastogi, R., Arora, N. M., Parashar, D., Paliwal, J., Naqvi, A., Srivastava, A., Singh, S. K., Kalyanaraman, S., Potdar, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.18.099234 · Cited by 14

Oxidative stress and endogenous DNA damage in blood mononuclear cells may predict anti-SARS-CoV-2 antibody titers after vaccination in older adults

Ntouros, P. A., Kravvariti, E., Vlachogiannis, N. I., Pappa, M. B., Trougakos, I. P., Terpos, E., Tektonidou, M. G., Souliotis, V. L., & Sfikakis, P. P. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166393 · Cited by 12

CoWIN: The Future of Universal Immunization Program in India

Arjun, M. C., Singh, A. K., & Parida, S. P. (2023) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_979_22 · Cited by 13

COVID-19 Vaccine Development in a Quadruple Helix Innovation System: Uncovering the Preferences of the Fourth Helix in the UAE

Niankara, I., Muqattash, R. S., Niankara, A., & Traoret, R. I. (2020) · Journal of Open Innovation Technology Market and Complexity · doi:10.3390/joitmc6040132 · Cited by 11

Nano COVID-19 Vaccines: the firsts RNA lipid nanoparticle vaccines being approved from history - Review

Pacheco, T. J. A., da Silva, V. C. M., & de Souza, D. G. (2020) · Research Society and Development · doi:10.33448/rsd-v9i12.11123 · Cited by 11

Exploring the myths surrounding the COVID-19 vaccines in Africa: the study to investigate their impacts on acceptance using online survey and social media

Lamptey, E., Senkyire, E. K., Serwaa, D., Aki, B. D., Boakye, E. O., Ikome, T., & Asamoah, A. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.2.193 · Cited by 11

A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine

Jawalagatti, V., Kirthika, P., Hewawaduge, C., Park, J.-Y., Yang, M., Oh, B., So, M. Y., Kim, B., & Lee, J. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.811802 · Cited by 11

SARS-CoV-2 Spike Protein-Activated Dendritic Cell-Derived Extracellular Vesicles Induce Antiviral Immunity in Mice

Barnwal, A., Basu, B., Tripathi, A., Soni, N., Mishra, D., Banerjee, A. K., Kumar, R., Vrati, S., & Bhattacharyya, J. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01094 · Cited by 11

Factors Associated with Adverse Reactions to BNT162b2 COVID-19 Vaccine in a Cohort of 3969 Hospital Workers

Rivera‐Izquierdo, M., Soler‐Iborte, E., de Rojas, J. P., Pegalajar‐García, M. D., Gil‐Villalba, A., Ruíz‐Villaverde, R., & Valero-Ubierna, M. D. C. (2021) · Vaccines · doi:10.3390/vaccines10010015 · Cited by 10

Implementation of immuno-chemoinformatics approaches to construct multi-epitope for vaccine development against Omicron and Delta SARS-CoV-2 variants

Dawood, A. A. (2022) · Vacunas · doi:10.1016/j.vacun.2022.05.006 · Cited by 11

Analytical Performance of a Multiplexed Microarray Assay for Rapid Identification and Quantification of a Multivalent mRNA Vaccine

Gerold, M. N., Toth, E., Blair, R. H., Gao, R. Y., Nadkarni, D. V., Barua, S., Woods, J., Rowlen, K. L., & Dawson, E. D. (2024) · Vaccines · doi:10.3390/vaccines12101144 · Cited by 8

Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines

Júnior, J. A. C. N., Santos, A. M., Cavalcante, R. C. M., Quintans‐Júnior, L. J., Walker, C. I. B., Borges, L. P., Frank, L. A., & Serafini, M. R. (2021) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2021.1908343 · Cited by 8

Accelerating SARS-CoV-2 Vaccine Development: Leveraging Novel Hybrid Deep Learning Models and Bioinformatics Analysis for Epitope Selection and Classification

Ameen, Z. S., Mostafa, H., Ozsahin, D. U., & Mubarak, A. S. (2023) · Processes · doi:10.3390/pr11061829 · Cited by 8

Recent Developments in Vaccines against Flaviviruses and Alphaviruses

Kim, Y. C., & Reyes‐Sandoval, A. (2023) · Vaccines · doi:10.3390/vaccines11020448 · Cited by 6

The Tragedy of Liberal Democratic Governance in the Face of Global Threats

Muraille, É., Naccache, P., & Pillot, J. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.902724 · Cited by 6

Level up for culture models - How 3D cell culture models benefit SARS-CoV-2 research

Häfner, S. J. (2021) · Biomedical Journal · doi:10.1016/j.bj.2021.02.001 · Cited by 5

Describing mRNA Vaccine Technology for a Military Audience

Biggs, A. T., & Littlejohn, L. F. (2022) · Military Medicine · doi:10.1093/milmed/usac129 · Cited by 5

Intranasal Immunization with Chitosan-PLGA-rOmp22 Protects Against Multidrug-Resistant Acinetobacter baumannii-Associated Pneumonia

Yang, N., Xue, J., Zhou, R., He, Y., Zhao, Y., Zhu, C., Shao, M., Gao, N., Fan, F., Feng, G., et al. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c01049 · Cited by 4

“Freedom and Dignity Are Worth More than Life”: The Dramatic Suicide of an Anti-Vax Man

Sablone, S., Spagnolo, L., Macorano, E., Ciavarella, M. C., Pascale, N., Strisciullo, G., Introna, F., & Fazio, A. D. (2022) · Healthcare · doi:10.3390/healthcare10112141 · Cited by 4

Development of Etf-3-specific nanobodies to prevent Ehrlichia infection and LNP-mRNA delivery in cellular and murine models

Duan, N., Lin, M., Zhang, W., Yan, Q., Chien, R. C., Budachetri, K., Denton, S. L., Kawahara, J., Lakritz, J., Zhong, Y., et al. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.128027 · Cited by 5

Preparatory phase for clinical trials of COVID-19 vaccine in Nepal

Gupta, G. P., Shah, Y., Pant, D. K., Lekhak, S. P., Shahi, R., Mandal, A., Poudel, P., Dumre, S. P., Pandey, K., & Pandey, B. D. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1809267 · Cited by 4

A Study on the Relationship between Banyuwangi Government Policy Mall Orang Sehat Mall of Health People with the Acceptance of the Coronavirus Disease 2019 Vaccine in Indonesian – Implications for Vaccination Implementation Policies

Pamungkas, A. Y. F., Trianita, D., Damayanti, F. E., Qomariyah, A., Wahyuni, L. E. T., Munif, B., & Wirawati, W. A. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.7388 · Cited by 5

What is the optimal country for minimum COVID-19 morbidity and mortality rates?

Arbel, Y., Arbel, Y., Kerner, A., & Kerner, M. (2023) · Environmental Science and Pollution Research · doi:10.1007/s11356-023-26632-y · Cited by 4

A required isolation index to support the health system during the pandemic of Covid-19 in Minas Gerais, Brazil

Versiani, A. F., de Sousa, R. G., Monteforte, P. T., Marciano, J. J. D. S., Nepomuceno, E. G., Nazaré, T. E. D., Lacerda, M. J., Barroso, M. F. S., Júnior, M. A. A., de Alvarenga, É. C., et al. (2021) · IEEE Latin America Transactions · doi:10.1109/tla.2021.9451241 · Cited by 4

A Hierarchy of Medical Countermeasures Against Biological Threats

Biggs, A. T., & Littlejohn, L. F. (2022) · Military Medicine · doi:10.1093/milmed/usac077 · Cited by 3

Viral-vectored vaccines against SARS-CoV-2

Kim, Y. C., & Reyes‐Sandoval, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90248-9.00003-6 · Cited by 2

Adaptive Leadership and Independent Opinions: Lessons From the National COVID-19 Immunisation Programme

Bulgiba, A. M. (2021) · Asia Pacific Journal of Public Health · doi:10.1177/10105395211065309 · Cited by 2

MultiPharm-DT: A Multi-Objective Decision Tool for Ligand-Based Virtual Screening Problems

Martín, S. P., Redondo, J. L., Ferrández, M. R., Pérez‐Sánchez, H., & Ortigosa, P. M. (2021) · Informatica · doi:10.15388/21-infor469 · Cited by 2

Engaging African diaspora in the fight against vaccine hesitancy

Ateghang-Awankem, B., & Anchang, K. Y. (2020) · American journal of public health research · doi:10.12691/ajphr-9-1-4 · Cited by 2

Vaccination Studies Against COVID-19 Agent: Current Status

Hıntıstan, S., & KAZAK, A. (2020) · Bezmialem Science · doi:10.14235/bas.galenos.2020.4669 · Cited by 2

COVID-19 vaccination status within anesthesia services: navigating uncharted waters

Goldstein, H. V., & Goldstein, J. C. (2021) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-021-01965-9 · Cited by 2

Infectious Disease and Epidemiology

Sattenspiel, L., & Orbann, C. (2023) · doi:10.1002/9781119828075.ch10 · Cited by 2

Recent Advances in Vaccine Development for Flaviviruses and Alphaviruses

Kim, Y. C., & Reyes‐Sandoval, A. (2025) · Vaccines · doi:10.3390/vaccines13080808 · Cited by 2

Knowledge and vaccination in COVID-19 management efficiency: a Global Malmquist-Luenberger index analysis

José, M. C. P., Márquez-Arenas, L., Povedano‐Fernández, P., Sara, R., & Gómez, J. L. Z. (2025) · Journal of Innovation & Knowledge · doi:10.1016/j.jik.2025.100867 · Cited by 1

Gene expression of ACE2 gene in patients infected with COVID-19 and comparing them with vaccine recipients

Mahmoud, M. A. K., & Khudhair, N. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00594 · Cited by 1

Immunological Interventions for the Management of Coronavirus Disease 2019 (COVID-19)

Chauhan, R. S., Malik, Y. S., Saminathan, M., & Tripathi, B. N. (2024) · Springer eBooks · doi:10.1007/978-981-99-2718-0_15 · Cited by 1

In search of a vaccine against COVID-19: implications for nursing practice

Boulton, J. (2020) · British Journal of Nursing · doi:10.12968/bjon.2020.29.16.948 · Cited by 1

Implementation of immuno-chemoinformatics approaches to construct multi-epitope for vaccine development against Omicron and Delta SARS-CoV-2 variants

Dawood, A. A. (2022) · Vacunas (English Edition) · doi:10.1016/j.vacune.2022.10.012 · Cited by 1

El sendero hacia la vacuna contra SARS-CoV-2

Marín, J. E. O. (2020) · ALERTA Revista Científica del Instituto Nacional de Salud · doi:10.5377/alerta.v3i2.9749

Making Pandora’s Box: The Politics of Science Funding

Allard, G. (2020) · TigerPrints (Clemson University)

Immunobiochemical Aspects in the Pathogenesis, Diagnosis, and Management of Novel Coronavirus (SARS-Cov-2) InfectionPreprint

Pinnelli, V. B. K., Sirsikar, M., Vandana, W. V., Mohanty, S., Wilma Delphine Silvia, C. R., Mohapatra, R. K., Vadakedath, S., & Kandi, V. (2020) · Preprints.org · doi:10.20944/preprints202009.0565.v1

Genomic Variation and Treatment Strategies of COVID-19: A Descriptive Review

Kundu, S., & Singh, S. (2021) · The Open COVID Journal · doi:10.2174/2666958702101010006

A novel coronavirus—from basic research to clinic

Luo, D., Wang, T., Tan, Z., Guo, S., Yu, Z., Liu, Y., ZHANG, Y., Wang, B., Gao, Y., Wang, H., et al. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2020-0233

Development of first Generation COVID-19 Vaccines: State-of the-Art Technologies and future Implications!

Mweetwa, L. L., Tlhoiwe, D., Tlhoiwe, T., Tshiamo, K. O., Munsaka, S. M., Kenaope, T. J., Mothibe, G., Mokate, O., & Oluwabusola, E. T. (2022) · Medical Research Archives · doi:10.18103/mra.v10i9.3027

The rapid progress in COVID vaccine development and implementation

Barrett, A. D. T., Titball, R. W., MacAry, P. A., Rupp, R. E., von Messling, V., Walker, D. H., & Fanget, N. V. J. (2022) · npj Vaccines · doi:10.1038/s41541-022-00442-8 · Cited by 35

COVID‐19: vaccine’s progress

Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13818 · Cited by 18

Recombinant Vaccines: The Revolution Ahead

Nayak, A. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_8

Vaccine Development Throughout History

Saleh, A., Qamar, S., Tekin, A., Singh, R., & Kashyap, R. (2021) · Cureus · doi:10.7759/cureus.16635 · Cited by 86